Screener
CRISPR Therapeutics CRSP Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's enterprise value?
- CRISPR Therapeutics (CRSP) reported enterprise value of $4.93B in Q1 2026.
- How has CRISPR Therapeutics's enterprise value changed year-over-year?
- CRISPR Therapeutics's enterprise value increased by 69.8% year-over-year, from $2.9B to $4.93B.
- What is the long-term trend for CRISPR Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's enterprise value has grown at a -14.5% compound annual growth rate (CAGR), from $10.61B to $4.86B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about CRISPR Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude